event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
It plays a central role in detoxification, immune function, and cellular protection
For a detailed comparison of these two tissue repair peptides, see our BPC-157 vs TB-500 research guide
[PubMed] [Google Scholar] 46.Mjasoedov NF, Andreeva LA, Grigorjeva ME, Obergan TY, Shubina TA, Lyapina LA: The influence of selank on the parameters of the hemostasis system, lipid profile, and blood sugar level in the course of experimental metabolic syndrome
The association of interleukin-1alpha and interleukin-1beta polymorphisms with the risk of Graves' disease in a case-control study and meta-analysis
